Business
ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights
EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights. The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO D
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CPLGUw1yVOurWsVIgzW3oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"text","content":"EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights.","length":402,"tagName":"p"},{"type":"text","content":"The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver. To join the session, please register using this link.","length":162,"tagName":"p"},{"type":"text","content":"About ONWARD Medical ","length":20,"tagName":"p"},{"type":"text","content":"ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company’s ARC-EX® System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM® with and without an implanted brain-computer interface (BCI).","length":752,"tagName":"p"},{"type":"text","content":"Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).","length...